|
FR2640638B1
(fr)
|
1988-12-20 |
1991-02-15 |
Commissariat Energie Atomique |
Bioreacteur et dispositif pour la culture de cellules animales
|
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
|
US5625048A
(en)
|
1994-11-10 |
1997-04-29 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
|
US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
|
US5741657A
(en)
|
1995-03-20 |
1998-04-21 |
The Regents Of The University Of California |
Fluorogenic substrates for β-lactamase and methods of use
|
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
|
US5756283A
(en)
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
|
US6506379B1
(en)
|
1995-06-07 |
2003-01-14 |
Ariad Gene Therapeutics, Inc. |
Intramuscular delivery of recombinant AAV
|
|
AU722624B2
(en)
|
1996-09-06 |
2000-08-10 |
Trustees Of The University Of Pennsylvania, The |
An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
|
|
CA2265460A1
(en)
|
1996-09-11 |
1998-03-19 |
The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services |
Aav4 vector and uses thereof
|
|
ES2278399T3
(es)
|
1996-11-20 |
2007-08-01 |
Introgen Therapeutics, Inc. |
Metodo mejorado para la produccion y purificacion de vectores adenovirales.
|
|
US6156303A
(en)
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
CA2304168A1
(en)
|
1997-09-19 |
1999-04-01 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
CA2303768C
(en)
|
1997-09-19 |
2009-11-24 |
The Trustees Of The University Of Pennsylvania |
Methods and vector constructs useful for production of recombinant aav
|
|
AU3097399A
(en)
|
1998-03-20 |
1999-10-11 |
Trustees Of The University Of Pennsylvania, The |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
US6953690B1
(en)
|
1998-03-20 |
2005-10-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
US6984517B1
(en)
|
1998-05-28 |
2006-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector and uses thereof
|
|
ES2340230T3
(es)
|
1998-11-10 |
2010-05-31 |
University Of North Carolina At Chapel Hill |
Vectores viricos y sus procedimientos de preparacion y administracion.
|
|
FR2786478B1
(fr)
|
1998-11-30 |
2000-12-22 |
Commissariat Energie Atomique |
Confinement du cesium et/ou du rubidium dans des ceramiques apatitiques
|
|
US6258595B1
(en)
|
1999-03-18 |
2001-07-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for helper-free production of recombinant adeno-associated viruses
|
|
JP4693244B2
(ja)
|
1999-03-18 |
2011-06-01 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
|
|
WO2000075353A1
(en)
|
1999-06-02 |
2000-12-14 |
Trustees Of The University Of Pennsylvania |
Compositions and methods useful for production of recombinant viruses which require helper viruses
|
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
|
AU1071701A
(en)
|
1999-09-29 |
2001-04-30 |
Trustees Of The University Of Pennsylvania, The |
Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
|
|
EP1373527A1
(en)
|
2001-04-06 |
2004-01-02 |
CropDesign N.V. |
The use of double and opposite recombination sites for the single step cloning of two dna segments
|
|
EP2017338A1
(en)
|
2001-05-24 |
2009-01-21 |
Genzyme Corporation |
Muscle-specific expression vectors
|
|
AU2002359284A1
(en)
|
2001-12-17 |
2003-06-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
|
|
US6845866B2
(en)
|
2002-10-10 |
2005-01-25 |
N. Henning Zieger |
Dispenser
|
|
US7605249B2
(en)
|
2002-11-26 |
2009-10-20 |
Medtronic, Inc. |
Treatment of neurodegenerative disease through intracranial delivery of siRNA
|
|
CN101410519B
(zh)
|
2003-04-25 |
2013-04-24 |
免疫医疗有限责任公司 |
间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
|
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
|
DE602004030327D1
(de)
|
2003-05-21 |
2011-01-13 |
Genzyme Corp |
Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
|
|
SI3235827T1
(sl)
|
2003-06-19 |
2021-05-31 |
Genzyme Corporation |
AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
|
|
US7291498B2
(en)
|
2003-06-20 |
2007-11-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
|
WO2005001103A2
(en)
|
2003-06-20 |
2005-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
CN1856576B
(zh)
|
2003-09-30 |
2011-05-04 |
宾夕法尼亚州立大学托管会 |
腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
|
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
|
WO2005072364A2
(en)
|
2004-01-27 |
2005-08-11 |
University Of Florida |
A modified baculovirus expression system for production of pseudotyped raav vector
|
|
EP1752536A4
(en)
|
2004-05-11 |
2008-04-16 |
Alphagen Co Ltd |
POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
EP2311967B1
(en)
|
2005-10-20 |
2017-09-20 |
UniQure IP B.V. |
Improved AAV vectors produced in insect cells
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
ES2385679T3
(es)
|
2006-08-24 |
2012-07-30 |
Virovek, Inc. |
Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
|
|
US20100203083A1
(en)
|
2007-05-31 |
2010-08-12 |
Medigene Ag |
Mutated structural protein of a parvovirus
|
|
EP2019143A1
(en)
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
JP5531225B2
(ja)
|
2008-07-09 |
2014-06-25 |
株式会社東芝 |
Ｘ線管用ターゲットおよびそれを用いたｘ線管、ｘ線検査装置ならびにｘ線管用ターゲットの製造方法
|
|
DE102008060558B4
(de)
|
2008-12-04 |
2013-09-26 |
Eduard Buzetzki |
Verfahren zum katalytischen Cracken von Pflanzenölen und tierischen Fetten
|
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
US9163261B2
(en)
|
2010-02-22 |
2015-10-20 |
Koteswara Rao KOLLIPARA |
Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer
|
|
EP2547781A4
(en)
|
2010-03-17 |
2014-04-23 |
Anaptysbio Inc |
PROCESS FOR PRODUCING TRANSCRIPTION PRODUCTS USING CRYPTIC SPLICE SITES
|
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
US10415056B2
(en)
|
2010-11-10 |
2019-09-17 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination
|
|
WO2012109570A1
(en)
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
HRP20171334T1
(hr)
|
2011-04-22 |
2017-11-17 |
The Regents Of The University Of California |
Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
|
|
ES2857773T5
(es)
|
2011-08-24 |
2024-06-04 |
Univ Leland Stanford Junior |
Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
|
|
WO2013096955A1
(en)
|
2011-12-23 |
2013-06-27 |
Case Western Reserve University |
Targeted gene modification using hybrid recombinant adeno-associated virus
|
|
US9644205B2
(en)
|
2012-04-25 |
2017-05-09 |
The Regents Of The University Of California |
Synthetic promoter for modulating gene expression
|
|
US9636370B2
(en)
|
2012-09-28 |
2017-05-02 |
The University Of North Carolina At Chapel Hill |
AAV vectors targeted to oligodendrocytes
|
|
EP2940131B1
(en)
|
2012-12-25 |
2019-02-20 |
Takara Bio Inc. |
Aav variant
|
|
US9567376B2
(en)
|
2013-02-08 |
2017-02-14 |
The Trustees Of The University Of Pennsylvania |
Enhanced AAV-mediated gene transfer for retinal therapies
|
|
JP6396988B2
(ja)
|
2013-03-15 |
2018-09-26 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
二重グリカン結合性ａａｖベクターのための方法および組成物
|
|
US11136557B2
(en)
|
2013-05-31 |
2021-10-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
WO2015164757A1
(en)
|
2014-04-25 |
2015-10-29 |
Oregon Health & Science University |
Methods of viral neutralizing antibody epitope mapping
|
|
IL248102B
(en)
|
2014-05-02 |
2022-07-01 |
Genzyme Corp |
aav vectors for gene therapy of the central nervous system and retina
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016005001A1
(en)
|
2014-07-11 |
2016-01-14 |
Huawei Technologies Co., Ltd. |
Network device, user device and methods of access signal broadcast
|
|
BR112017005892A2
(pt)
|
2014-09-24 |
2017-12-12 |
Hope City |
variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
AU2015335923B2
(en)
|
2014-10-21 |
2021-04-29 |
University Of Massachusetts |
Recombinant AAV variants and uses thereof
|
|
SG11201703148TA
(en)
|
2014-11-05 |
2017-05-30 |
Voyager Therapeutics Inc |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
WO2016081811A1
(en)
|
2014-11-21 |
2016-05-26 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
WO2016126857A1
(en)
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
CA2977355A1
(en)
|
2015-02-20 |
2016-08-25 |
University Of Iowa Research Foundation |
Methods and compositions for treating genetic eye diseases
|
|
CN106032540B
(zh)
|
2015-03-16 |
2019-10-25 |
中国科学院上海生命科学研究院 |
CRISPR/Cas9核酸内切酶体系的腺相关病毒载体构建及其用途
|
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
EP3280451B8
(en)
|
2015-04-08 |
2019-09-25 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
WO2017015102A1
(en)
|
2015-07-17 |
2017-01-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for achieving high levels of transduction in human liver cells
|
|
BR112018003665A2
(en)
|
2015-09-28 |
2018-09-25 |
The University Of North Carolina At Chapel Hill |
methods and compositions for antibody evasion viral vectors
|
|
WO2017066764A2
(en)
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
|
|
WO2017083722A1
(en)
|
2015-11-11 |
2017-05-18 |
Greenberg Kenneth P |
Crispr compositions and methods of using the same for gene therapy
|
|
US10240145B2
(en)
|
2015-11-25 |
2019-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
|
|
KR102423442B1
(ko)
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
CN106884014B
(zh)
|
2015-12-16 |
2020-11-13 |
北京五加和基因科技有限公司 |
腺相关病毒反向末端重复序列突变体及其应用
|
|
US10179176B2
(en)
|
2016-02-16 |
2019-01-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
|
|
EP3423154B1
(en)
|
2016-03-01 |
2021-05-05 |
Intraop Medical Corporation |
Low energy electron beam radiation system that generates electron beams with precisely controlled and adjustable penetration depth useful for therapeutic applications
|
|
EP3827812B1
(en)
|
2016-07-29 |
2025-10-29 |
The Regents of the University of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US20190262373A1
(en)
|
2016-08-16 |
2019-08-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
US20200316221A1
(en)
|
2016-10-13 |
2020-10-08 |
University Of Massachusetts |
Aav capsid designs
|
|
EP3558393A4
(en)
|
2016-12-22 |
2020-11-11 |
Oregon Health & Science University |
ADENO-ASSOCIATED VIRAL VECTORS
|
|
CN108330147A
(zh)
|
2017-01-20 |
2018-07-27 |
上海吉凯基因化学技术有限公司 |
一种重组腺相关病毒载体生产工艺的建立
|
|
US11680275B2
(en)
*
|
2017-06-06 |
2023-06-20 |
University Of Massachusetts |
Self-regulating AAV vectors for safe expression of MeCP2 in rett syndrome
|
|
MX2020000244A
(es)
|
2017-06-27 |
2020-09-28 |
Regeneron Pharma |
Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas.
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖを送達するための組成物および方法
|
|
SG11202002276VA
(en)
|
2017-09-20 |
2020-04-29 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
|
WO2019068854A1
(en)
|
2017-10-06 |
2019-04-11 |
Ospedale San Raffaele S.R.L. |
GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
BR112020016699A2
(pt)
|
2018-02-28 |
2020-12-15 |
The University Of North Carolina At Chapel Hill |
Métodos e composições para vetores de vírus de evasão de anticorpos
|
|
JP2021523702A
(ja)
|
2018-05-04 |
2021-09-09 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ
|
|
WO2019216932A1
(en)
*
|
2018-05-07 |
2019-11-14 |
The University Of North Carolina At Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
US11821009B2
(en)
|
2018-05-15 |
2023-11-21 |
Cornell University |
Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
|
|
SG11202011151VA
(en)
|
2018-05-15 |
2020-12-30 |
Univ Washington |
Compositions and methods for reducing spliceopathy and treating rna dominance disorders
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
EP3793615A2
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Directed evolution of aav to improve tropism for cns
|
|
CN112703198B
(zh)
*
|
2018-07-11 |
2025-05-30 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
US20210277418A1
(en)
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020068990A1
(en)
|
2018-09-26 |
2020-04-02 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
US12281321B2
(en)
*
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3861010A1
(en)
|
2018-10-02 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN113395975A
(zh)
|
2018-11-20 |
2021-09-14 |
宾夕法尼亚州大学信托人 |
用于靶向血脑屏障的组合物和方法
|
|
WO2020132455A1
(en)
|
2018-12-21 |
2020-06-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
WO2020154324A1
(en)
|
2019-01-22 |
2020-07-30 |
Ix Layer Inc. |
Systems and methods for access management and clustering of genomic or phenotype data
|
|
EP3917945A4
(en)
|
2019-01-30 |
2023-02-08 |
The Broad Institute Inc. |
ADVANCED ADENO-ASSOCIATED VIRUS (AAVS) TARGETED DELIVERY SYSTEMS
|
|
KR20210130158A
(ko)
|
2019-01-31 |
2021-10-29 |
오레곤 헬스 앤드 사이언스 유니버시티 |
Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
|
|
BR112021018776A2
(pt)
|
2019-03-21 |
2021-11-30 |
Stridebio Inc |
Vetores de vírus adenoassociado recombinante
|
|
EP3715358A1
(en)
|
2019-03-28 |
2020-09-30 |
Universität zu Köln |
Mutated adeno-associated virus capsid proteins, aav particle comprising the same and liver directed aav vector gene therapy
|
|
CN114450411A
(zh)
|
2019-04-01 |
2022-05-06 |
特纳亚治疗股份有限公司 |
具有工程化衣壳的腺相关病毒
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
AU2020271108A1
(en)
|
2019-04-11 |
2021-11-11 |
California Institute Of Technology |
Virus compositions with enhanced specificity in the brain
|
|
EP3959226A2
(en)
|
2019-04-26 |
2022-03-02 |
Sangamo Therapeutics, Inc. |
Engineering aav
|
|
TW202532428A
(zh)
|
2019-04-26 |
2025-08-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2021025995A1
(en)
|
2019-08-02 |
2021-02-11 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220403414A1
(en)
|
2019-10-16 |
2022-12-22 |
Wuxi Apptec (Shanghai) Co., Ltd. |
Novel aav variant
|
|
EP4431524A3
(en)
|
2019-12-04 |
2024-12-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancing blood-brain barrier drug transport by targeting endogenous regulators
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
IL297391A
(en)
|
2020-04-20 |
2022-12-01 |
Tenaya Therapeutics Inc |
An adeno-associated virus with an engineered capsid
|
|
AU2021264061A1
(en)
|
2020-05-01 |
2022-12-01 |
Massachusetts Institute Of Technology |
Engineered central nervous system compositions
|
|
US12209251B2
(en)
|
2020-05-05 |
2025-01-28 |
The University Of North Carolina At Chapel Hill |
Modified adeno-associated virus 5 capsids and uses thereof
|
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
|
CN116390934A
(zh)
|
2020-05-26 |
2023-07-04 |
塑造治疗公司 |
功能性aav衣壳的高通量工程化
|
|
CA3192600A1
(en)
|
2020-08-21 |
2022-02-24 |
Capsida, Inc. |
Adeno-associated virus compositions having preferred expression levels
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4322974A4
(en)
|
2021-04-13 |
2025-06-25 |
Capsida, Inc. |
Adeno-associated virus compositions having increased brain enrichment
|
|
EP4322976A4
(en)
|
2021-04-13 |
2025-06-25 |
Capsida, Inc. |
AAV COMPOSITIONS WITH HIGH EXPRESSION LEVELS IN THE BRAIN
|
|
EP4323013A4
(en)
|
2021-04-13 |
2025-06-25 |
Capsida, Inc. |
SELECTED AAV COMPOSITIONS WITH PREFERRED BRAIN ENRICHEMENT
|
|
WO2022221421A2
(en)
|
2021-04-13 |
2022-10-20 |
Capsida, Inc. |
Aav compositions with high brain expression for treating mucopolysaccharidosis ii
|
|
WO2022235702A1
(en)
|
2021-05-04 |
2022-11-10 |
California Institute Of Technology |
Recombinant aavs for delivery to central nervous system and brain vasculature
|
|
EP4373834A4
(en)
|
2021-07-23 |
2025-06-04 |
California Institute of Technology |
VIRAL VECTORS FOR ENHANCED ULTRASOUND-INDUCED DELIVERY TO THE BRAIN
|
|
WO2023044306A1
(en)
|
2021-09-14 |
2023-03-23 |
California Institute Of Technology |
Aav capsid variants
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20240382617A1
(en)
|
2021-09-21 |
2024-11-21 |
Capsida Biotherapeutics, Inc. |
Virus compositions to efficiently target the nervous system and the lungs
|
|
MX2024004936A
(es)
|
2021-11-02 |
2024-05-08 |
Voyager Therapeutics Inc |
Variantes de capsides de aav y sus usos.
|
|
US20250001007A1
(en)
|
2021-11-16 |
2025-01-02 |
California Institute Of Technology |
Adeno-associated virus compositions having preferred heart and skeletal muscle enrichment
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023092002A2
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis and disorders associatedwith the spinal cord
|
|
TW202334181A
(zh)
|
2021-11-17 |
2023-09-01 |
美商航海家醫療公司 |
Ａａｖ蛋白殼變異體及其用途
|
|
EP4433490A2
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CA3249551A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
CN119095865A
(zh)
|
2022-03-03 |
2024-12-06 |
加州理工学院 |
用于跨越血脑屏障的组合物和方法
|
|
CA3254570A1
(en)
|
2022-03-24 |
2023-09-28 |
Capsida, Inc. |
ADENE-ASSOCIATED VIRUS COMPOSITIONS WITH INCREASED CARDIAC ENRICHEMENT
|
|
KR20240162556A
(ko)
|
2022-03-24 |
2024-11-15 |
캡시다, 인크. |
바람직한 뇌 풍부화를 갖는 선택된 aav 조성물
|
|
JP2025512333A
(ja)
|
2022-04-11 |
2025-04-17 |
テナヤ セラピューティクス， インコーポレイテッド |
操作されたカプシドを伴うアデノ随伴ウイルス
|
|
WO2023215546A2
(en)
|
2022-05-06 |
2023-11-09 |
Capsida, Inc. |
Adeno-associated virus compositions having increased brain enrichment
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
KR20250017219A
(ko)
|
2022-05-17 |
2025-02-04 |
캡시다, 인크. |
바람직한 뇌, 척수, 및/또는 심장 발현 수준을 갖는 선택된 아데노-연관 바이러스 조성물
|
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
US20250255989A1
(en)
|
2022-06-16 |
2025-08-14 |
Capsida, Inc |
Adeno-associated virus compositions having increased brain enrichment and/or heart enrichment
|
|
EP4540395A1
(en)
|
2022-06-16 |
2025-04-23 |
Capsida, Inc. |
Adeno-associated virus compositions having increased brain enrichment and decreased liver enrichment
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
AR129733A1
(es)
|
2022-06-28 |
2024-09-25 |
Voyager Therapeutics Inc |
Variantes de cápsides de aav y sus usos
|
|
AR129843A1
(es)
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
CA3266790A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
TAU PROTEIN BINDING COMPOUNDS
|
|
CN120265647A
(zh)
|
2022-10-19 |
2025-07-04 |
卡西达生物疗法股份有限公司 |
具有优选脑富集和低肝富集的腺相关病毒组合物
|
|
WO2024086747A1
(en)
|
2022-10-19 |
2024-04-25 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
AU2023367210A1
(en)
|
2022-10-27 |
2025-05-01 |
California Institute Of Technology |
Targets for receptor-mediated control of therapeutic biodistribution and efficacy
|
|
KR20250131772A
(ko)
|
2022-11-13 |
2025-09-03 |
알렉시온 파마 인터내셔널 오퍼레이션즈 리미티드 |
전두측두엽 치매에 대한 유전자 요법
|
|
TW202502803A
(zh)
|
2023-03-10 |
2025-01-16 |
美商戴諾治療公司 |
衣殼多肽及其使用方法
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP4705324A1
(en)
|
2023-05-02 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2024229164A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2024229173A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
CN121127597A
(zh)
|
2023-05-03 |
2025-12-12 |
沃雅戈治疗公司 |
用于治疗与葡糖苷酰鞘氨醇酶β1缺陷相关的病症的组合物及方法
|
|
EP4705487A2
(en)
|
2023-05-03 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
WO2024229167A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
PE20260124A1
(es)
|
2023-05-03 |
2026-01-16 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos relacionados con la deficiencia de cdkl5
|
|
WO2024229389A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4705488A1
(en)
|
2023-05-04 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
AU2024274127A1
(en)
|
2023-05-15 |
2025-11-13 |
Sangamo Therapeutics, Inc. |
Fitness maturation of engineered aav capsid stac-102
|
|
AU2024271436A1
(en)
|
2023-05-15 |
2025-11-13 |
Sangamo Therapeutics, Inc. |
Engineered blood brain barrier penetrant aav capsids
|
|
WO2025038802A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025038430A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025038796A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025038795A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
AR133562A1
(es)
|
2023-08-16 |
2025-10-08 |
Voyager Therapeutics Inc |
Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina
|
|
WO2025038805A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|